{
  "docId": "019de070-c9e1-7644-aac7-afa340d8795d",
  "docSlug": "fc9db8b68eed863ebdeb09cbc0c7e18a",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 86 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 86,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Slide presents data from PROMIS observational trial and SATELLITE Phase IIa trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c9e1-7644-aac7-afa340d8795d/38",
  "deckHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d",
  "deckJsonHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d.json",
  "deckAnchorHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.22,
        "x": 0.51,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Improved quality of life at day 90",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e7c9d1f-6610-42f5-8b38-83a314388067",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.22,
        "x": 0.75,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Reduced NT-proBNP",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bcb6592-858a-415d-98ac-f63faa56606d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.22,
        "x": 0.27,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Trend towards 6MWD improvement",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95d37671-a298-4c8c-b41e-7b4a582b4165",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.22,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "chart",
      "text": "PROMIS observational trial in HFpEF patients",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9027a9ac-f945-4406-ab0f-31daa9c55e00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1. Six-minute walk distance 2. The Kansas City Cardiomyopathy Questionnaire 3. N-terminal pro-B-type natriuretic peptide, an established biomarker for heart failure. Source: AstraZeneca data on file.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ce41db0-7624-47ff-a842-361a503e076b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.27,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "SATELLITE Phase IIa: improved symptomatic and biomarker endpoints. Phase IIb start in H1 2021",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4f09dfa-6613-4abd-a082-c1e1d0dc1ae7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "AZD4831: small-molecule MPO inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a577285f-ebd8-42ba-937e-c45e921f17e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Targeting blood vessels inflammation and fibrosis",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b676f6b1-376c-4243-a6de-93d2535391aa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 41,
      "from": 36,
      "beatId": "420d707b-2958-4b32-ba18-2b50cdf7f871",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slides 36-41 provide an overview of the market opportunity",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}